A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis
10.3760/cma.j.issn.0578-1426.2009.07.012
- VernacularTitle:来氟米特与甲氨蝶呤治疗银屑病关节炎关节病变的临床研究
- Author:
Gailian ZHANG
;
Feng HUANG
;
Jianglin ZHANG
;
Xiaofeng LI
- Publication Type:Journal Article
- Keywords:
Psoriasis,arthritic;
Leflunomide;
Methotrexate;
Treatment outcome;
Safety
- From:
Chinese Journal of Internal Medicine
2009;48(7):570-574
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety profile of methotrexate (MTX), leflunomide (LEF) and low-dose MTX and LEF (MTX + LEF) combined treatment for psoriatic arthritis (PsA). Methods This was a 24 weeks, two-center, open-labeled, controlled trial All subjects fulfilled the moll and wright criteria for definite PsA. Subjects were given one of the 3 regimens, MTX, or LEF, or MTX + LEF. The primary end point was proportion of psoriatic arthritis response criteria(PsARC)response. The secondary end point was proportion of modified 20% improvement of American College of Rheumatolngy (ACR20) response. Results At week 24, the percent of patients achieving PsARC in MTX, LEF and MTX + LEF group were 75.0% ,68. 8% ,83.3% respectively, and the percent of patients achieving ACR20 were 66. 7% ,50. 0% ,83. 3% respectively. At week 24, tender joint counts, swollen joint counts, patient's assessment of pain, patient's global assessment (PGA), physician' s global assessment, health assessment questionnaire(HAQ)were significantly improved compared with base-line values(P <0. 05). At week 24, the improvement of patient's assessment of pain, HAQ, ESR were better in the MTX + LEF group compared with LEF group while the improvement of patient's assessment of pain, PGA, HAQ, ESR were better in the MTX group compared with LEF group (P < 0. 05). The incidence of treatment related adverse events was 38.5%, 38. 9% and 35% in MTX, LEF and MTX + LEF group respectively. There was no serious adverse reactions. Conclusion Low dose MTX + LEF regimen showed similar good efficacy and safety profde for PsA patients.
